Compare SVV & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVV | DMRA |
|---|---|---|
| Founded | 1954 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2020 |
| Metric | SVV | DMRA |
|---|---|---|
| Price | $9.48 | $22.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $13.67 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 1.3M | 329.5K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,678,954,000.00 | N/A |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $7.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.19 | N/A |
| 52 Week Low | $6.91 | $16.50 |
| 52 Week High | $13.89 | $28.76 |
| Indicator | SVV | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.78 | 37.71 |
| Support Level | $9.03 | $16.50 |
| Resistance Level | $9.98 | $26.66 |
| Average True Range (ATR) | 0.41 | 1.44 |
| MACD | 0.20 | -0.18 |
| Stochastic Oscillator | 99.43 | 7.82 |
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.